Also Known As
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
This article was last reviewed on
This article waslast modified on
December 4, 2017.
What is lung cancer?

Lung cancer is the uncontrolled growth of abnormal cells originating within the lungs, usually in the layers of cells that line the air passages. These abnormal cells do not go through the natural stages of growth, division, and dying that normal cells do. They replicate unchecked, often forming one or more masses of cells (tumors). Tumors can damage healthy tissue and grow large enough to interfere with breathing. Lung cancer can eventually spread (metastasize) beyond the lungs into nearby lymph nodes, tissues, and other organs.

The lungs are part of the respiratory (breathing) system and are located in the chest, inside the rib cage and above the diaphragm. When a person inhales, air enters the lungs and flows through passages of decreasing diameter called bronchi and bronchioles. These passages carry oxygen to small sacs (alveoli) deep within the lung, where oxygen moves from the lung into the bloodstream, and carbon dioxide, a byproduct of metabolism, moves from the blood into the lung to be exhaled. Any lung disease that interferes with this exchange process, including lung cancer, can limit the amount of oxygen available and affect tissues and organs throughout the body.

According to the American Cancer Society (ACS), lung cancer is the second most common cancer in both men and women (other than skin cancer) and it is the leading cause of cancer death. More people die of lung cancer each year than of breast, prostate, and colon cancer combined. The ACS estimates that in 2013 there will be about 228,000 new cases of lung cancer in the U.S. and as many as 159,000 people will die of the disease. While anyone can get lung cancer, about 2 out of 3 new cases will be in people 65 years of age or older.

    Lung cancer begins in one of the cell types that exist in the lungs. Most cases are thought to be due to an acquired genetic change or mutation in DNA that leads to the production of an abnormal protein that either promotes the uncontrolled growth of cells or inhibits their natural death.

    Cancer that spreads from another part of the body to the lungs, such as metastatic breast cancer, is not considered lung cancer. Cancers that have spread to the lungs from other areas are treated differently so they are not covered in this article.

    Accordion Title
    About Lung Cancer
    • Risk Factors

      Risk factors for developing lung cancer include:

      • Smoking – at least 80% of lung cancer deaths are thought to be related to smoking. The more a person smokes, and the longer that he or she smokes, the greater the risk. Second-hand smoke also increases risk of lung cancer.
      • Radon exposure – a common cause of lung cancer in nonsmokers; it is a colorless, odorless radioactive gas that occurs naturally in soil but can accumulate in some homes.
      • Asbestos exposure – this can increase the risk of lung cancer. Asbestos is more commonly associated with mesothelioma, a rare cancer of the lining of the chest and abdomen. Most cases of mesothelioma – about 70% to 80% – arise in people with a history of working with asbestos, especially in the shipbuilding, construction, automotive, and fireproofing industries.
      • Exposure to cancer-causing substances (carcinogens) such as arsenic or chromium (often in the workplace)
      • Radiation therapy – such as previous treatment for another type of cancer
      • Family or personal history of lung cancer
    • Types

      There are two main categories of lung cancer, non-small cell and small cell. These cancers are named and differentiated based upon the size, shape, and characteristics of the tumor cells. In addition, there are several less common types of cancer that can affect the lungs. 

      The following table lists the different types of lung cancers.

      Type of Lung Cancer Percentage of Lung Cancers Comments
      Non-small cell lung cancer (NSCLC) 85-90% Most cases of lung cancer are in this category.
      • Squamous cell (epidermoid) carcinoma
      25-30% Squamous cells are flat cells that are normally found in the skin, mouth and throat but not the lungs. They develop in the lungs in response to ongoing injury; this type of lung cancer is primarily seen in smokers.
      • Adenocarcinoma
      40% This is cancer that originates in the cells that secrete mucus; mainly seen in current or former smokers but is also the most common type seen in non-smokers.
      • Large cell (undifferentiated) carcinoma
      10-15% This type tends to grow and spread quickly. It also occurs mainly in smokers.
      • Various subtypes
      Much less common Examples include adenosquamous carcinoma and sarcomatoid carcinoma.
      Small cell lung cancer (SCLC) 10-15% Also known as oat cell cancer and small cell undifferentiated carcinoma; this type is primarily seen in smokers.
      Others    
      Lung carcinoid tumors Less than 5% Most often are slow-growing.
      Other tumors found in the lungs Rare Examples include sarcomas, lymphomas.
    • Signs and Symptoms

      It is difficult to detect lung cancer at an early stage. There are often no symptoms until the condition is well advanced. Examples of symptoms include:

      • Persistent cough
      • Persistent or recurrent lung infections (e.g., pneumonia, bronchitis)
      • Hoarseness
      • Shortness of breath
      • Wheezing
      • Chest pain
      • Fatigue or weakness
      • Weight loss
      • Loss of appetite
      • Coughing up blood


      When lung cancer spreads (metastasizes) to other areas of the body, other signs and symptoms related to those sites may develop. Examples include bone pain, neurological symptoms, and swollen lymph nodes.

    • Tests

      The goals with testing for lung cancer are to detect it as soon as possible, determine the specific type and how far it has spread, help guide treatment, and evaluate a person's general state of health and lung function.

      Screening
      There are no blood tests that can be used to screen for or detect lung cancer. However, recent guidelines from the American College of Chest Physicians, American Cancer Society, and National Comprehensive Cancer Network recommend that people who have a significant risk of developing lung cancer due to age and previous or current smoking history be offered periodic low-dose computed tomography (LDCT) scanning to help detect early lung cancer. This recommendation is limited to those at a significant risk, and screening should only be done by facilities that are experienced with the procedure. For information on this type of procedure, visit RadiologyInfo.org: Computed tomography, chest.

      Sometimes a chest X-ray may be used to observe the lungs and nearby structures to look for tumors. Likewise, sputum cytology, a method of obtaining cells from the lungs, may be used to look for cancer cells. However, these procedures are not recommended for screening purposes by any established guidelines.

      Diagnosis and Staging
      A diagnosis of lung cancer is usually confirmed by examining tissue and/or cells from the lungs with a microscope. If the tissue or cells are cancerous, the next step is to determine the stage (or extent) of disease. Treatment will depend in part on the "stage" of the cancer; it is categorized by how far it has spread from its original site. Tests used for diagnosis and staging include:

      • Biopsy – when a suspected cancer is found, a biopsy is taken, removing some tissue from the suspicious site for examination under a microscope by a pathologist. A sample of cells may be collected by inserting a small needle into the lungs and aspirating the cells (sometimes called a needle biopsy, fine needle aspiration or FNA). More commonly, a long, thin, lighted tube called a bronchoscope may be inserted into the airways to view the structures and collect a tissue sample. In some cases, a sample of tissue may be collected during a surgical procedure.
      • Cytology – this procedure may be used to help establish a diagnosis of lung cancer by examining cells in a sample of fluid collected during a bronchoscope examination or in a sample of sputum. Sputum samples (deep respiratory secretions, not saliva) may be coughed up and expelled into a sterile cup provided by the laboratory. If a person cannot produce a sputum sample, then it can often be induced by inhaling a sterile saline or glycerin aerosol for several minutes to loosen phlegm in the lungs.
      • Pleural fluid analysis – this is an evaluation of fluid removed from the space between the lungs and chest wall by a procedure called thoracentesis. It may be used as part of staging to help determine whether cancer has spread to the outside lining of the lungs. This is only done in people who have an increased amount of fluid in this space since normally the amount of fluid present is too small to sample safely.


      Staging may also involve other evaluations, such as a physical exam or imaging tests that look for evidence of cancer in other organs or parts of the body.

      Guide Treatment
      Tests may be performed on tumor tissue to help guide therapy. Some people with non-small cell lung cancer (NSCLC) may be candidates for targeted therapy, depending on the type of NSCLC and results of some molecular tests. Targeted therapy is a newer type of cancer treatment that uses drugs that have a greater effect on cancerous tissue, reducing many of the side effects associated with standard therapy. It is based on the fact that the genetic makeup of the cancer cells is different than the normal cells around them. Targeted therapy aims to disrupt specific steps or processes that are somewhat unique to the growth of cancer cells.

      Testing may include:

      • EGFR gene mutation – present in 10% to 15% of adenocarcinoma non-small cell lung cancers (see the table of types of lung cancers on the Overview page). If present, a person is more likely to respond to tyrosine kinase inhibitor drug therapies such as gefitinib and erlotinib.
      • KRAS gene mutation – includes 20% to 30% of adenocarcinoma non-small cell lung cancers. If present, a person is less likely to respond to tyrosine kinase inhibitors.
      • ALK gene mutation / gene rearrangement (EML4-ALK, about 5% of non-small cell lung cancers) – most often seen in light smokers or non-smokers with adenocarcinoma. If a mutation is present, the cancer is more likely to respond to ALK kinase inhibitors such as crizotinib and less likely to respond to tyrosine kinase inhibitors.
      • ROS1 gene mutation (1% to 2% of adenocarcinoma non-small cell lung cancers) – those with gene rearrangement are more likely to respond to crizotinib and less likely to respond to tyrosine kinase inhibitors.


      Other laboratory tests
      General testing is often used to help assess an affected person's health and/or to monitor them during treatment. Some of these tests may include:


      Non-laboratory tests
      Pulmonary function tests (PFTs) may be used to help evaluate lung function. For more complete information, visit the web site for Johns Hopkins Medicine: Pulmonary Function Laboratory.

      A variety of imaging tests are used to help diagnose and stage lung cancers. They include:

      • Chest x-ray
      • Computed tomography (CT) scan
      • Magnetic resonance imaging (MRI) scan
      • Positron emission tomography (PET) scan
      • Ultrasound
      • Bone scan


      For additional details about these procedures, visit RadiologyInfo.org.

    • Treatment

      Appropriate lung cancer treatment depends upon the type of cancer, its stage, and its characteristics. Staging evaluates the size of the cancer, its location, and how far it has spread. Treatments may include:

      • Surgery to remove part of a lobe of a lung, a lobe of a lung, or an entire lung
      • Surgery to help relieve symptoms such as airway blockages or fluid buildup
      • Radiation therapy
      • Chemotherapy
      • Targeted therapy
      • Drugs that target tumor blood vessel growth (angiogenesis)
      • Drugs that target EGFR (epidermal growth factor receptor) – tyrosine kinase inhibitor drug therapies such as gefitinib and erlotinib
      • Drugs that target the protein made by an altered ALK gene, such as crizotinib


      People who become resistant to available treatments and/or have inoperable lung cancer may want to consider enrollment in clinical trials of new treatments. There are promising areas of research that may offer them additional options. For more on this see Clinicaltrials.gov.

    View Sources

    NOTE: This article is based on research that utilizes the sources cited here as well as the collective experience of the Lab Tests Online Editorial Review Board. This article is periodically reviewed by the Editorial Board and may be updated as a result of the review. Any new sources cited will be added to the list and distinguished from the original sources used.

    (Revised 2013 July 12). Lung Cancer (Non-Small Cell). American Cancer Society [On-line information]. Available online at [On-line information]. Available online at http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/index through http://www.cancer.org. Accessed July 2013.

    (Revised 2013 June 6). Lung Cancer (Small Cell). American Cancer Society [On-line information]. Available online at http://www.cancer.org/cancer/lungcancer-smallcell/detailedguide/index through http://www.cancer.org. Accessed July 2013.

    (Revised 2012 August 15). Lung Carcinoid Tumor. American Cancer Society [On-line information]. Available online at http://www.cancer.org/cancer/lungcarcinoidtumor/detailedguide/index through http://www.cancer.org. Accessed July 2013.

    Tan, W. and Huq, S. (Updated 2013 July 23) Non-Small Cell Lung Cancer. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/279960-overview#showall through http://emedicine.medscape.com. Accessed July 2013.

    Markman, M. (Updated 2013 July 15) Genetics of Non-Small Cell Lung Cancer. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/1689988-overview through http://emedicine.medscape.com. Accessed July 2013.

    Tan, W. and Maghfoor, I. (Updated 2012 December 27). Small Cell Lung Cancer. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/280104-overview through http://emedicine.medscape.com. Accessed July 2013.

    (Updated 2012 April 17). Lung Cancer and the Environment. Centers for Disease Control and Prevention [On-line information]. Available online at http://ephtracking.cdc.gov/showCancerLcEnv.action through http://ephtracking.cdc.gov. Accessed July 2013.

    Chen, Y. (Updated 2011 August 24). Updated by: Yi-Bin Chen, MD Lung cancer. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/007270.htm. Accessed July 2013.

    (2012 September 17). What You Need To Know About™ Lung Cancer. National Cancer Institute [On-line information]. Available online at http://www.cancer.gov/cancertopics/wyntk/lung through http://www.cancer.gov. Accessed July 2013.

    Nelson, R. (2013 July 17). Lung Cancer Screening Benefits Those at Highest Risk. Medscape Today News from N Engl J Med v 369: 245-254 [On-line information]. Available online at http://www.medscape.com/viewarticle/807979 through http://www.medscape.com. Accessed July 2013.

    Mayo Clinic staff (2012 April 17). Lung cancer. Mayo Clinic [On-line information]. Available online at http://www.mayoclinic.com/print/lung-cancer/DS00038/METHOD=print&DSECTION=all through http://www.mayoclinic.com. Accessed July 2013.

    Chen, Y. (Updated 2011 August 24). Lung cancer - non-small cell. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/007194.htm. Accessed July 2013.

    Dugdale, D. (Updated 2011 August 24). Lung cancer - small cell. MedlinePlus Medical Encyclopedia [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/000122.htm. Accessed July 2013.

    Nelson, R. (2013 May 07). ACCP Issues New Guidelines for Lung Cancer Screening. Medscape Today News from Chest. 2013;143(5_suppl):e78S-e92S. [On-line information]. Available online at http://www.medscape.com/viewarticle/803769 through http://www.medscape.com. Accessed July 2013

    Ellison, G. et. al. (2013). EGFR Mutation Testing in Lung Cancer, A Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. Medscape Today News from J Clin Pathol. 2013;66(2):79-89. [On-line information]. Available online at http://www.medscape.com/viewarticle/778512 through http://www.medscape.com. Accessed July 2013.

    West, H. J. (2013 February 13). KRAS+ Lung Cancer Responds to Targeted Therapy. Medscape Today News. Lancet Oncol. v14 38-47. [On-line information]. Available online at http://www.medscape.com/viewarticle/779075 through http://www.medscape.com. Accessed July 2013.

    Markman, M. (Updated 2013 July 15). Genetics of Non-Small Cell Lung Cancer. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/1689988-overview through http://emedicine.medscape.com. Accessed July 2013.

    Anderson, S. (2011). Laboratory Methods for KRAS Mutation Analysis. Medscape Reference from Expert Rev Mol Diagn. v11 (6) 635-642 [On-line information]. Available online at http://www.medscape.com/viewarticle/746638 through http://www.medscape.com. Accessed July 2013.